Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLK3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217627 | Esophagus | HGIN | regulation of protein catabolic process | 119/2587 | 391/18723 | 8.09e-18 | 2.43e-15 | 119 |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:004586227 | Esophagus | HGIN | positive regulation of proteolysis | 107/2587 | 372/18723 | 2.61e-14 | 4.60e-12 | 107 |
GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
GO:190336227 | Esophagus | HGIN | regulation of cellular protein catabolic process | 81/2587 | 255/18723 | 1.16e-13 | 1.93e-11 | 81 |
GO:000989626 | Esophagus | HGIN | positive regulation of catabolic process | 126/2587 | 492/18723 | 1.46e-12 | 2.09e-10 | 126 |
GO:003133126 | Esophagus | HGIN | positive regulation of cellular catabolic process | 112/2587 | 427/18723 | 5.15e-12 | 6.72e-10 | 112 |
GO:190305027 | Esophagus | HGIN | regulation of proteolysis involved in cellular protein catabolic process | 70/2587 | 221/18723 | 6.21e-12 | 7.76e-10 | 70 |
GO:006113627 | Esophagus | HGIN | regulation of proteasomal protein catabolic process | 60/2587 | 187/18723 | 1.10e-10 | 1.12e-08 | 60 |
GO:004573227 | Esophagus | HGIN | positive regulation of protein catabolic process | 69/2587 | 231/18723 | 1.66e-10 | 1.64e-08 | 69 |
GO:200005827 | Esophagus | HGIN | regulation of ubiquitin-dependent protein catabolic process | 53/2587 | 164/18723 | 9.89e-10 | 8.13e-08 | 53 |
GO:190336427 | Esophagus | HGIN | positive regulation of cellular protein catabolic process | 51/2587 | 155/18723 | 1.01e-09 | 8.15e-08 | 51 |
GO:001050616 | Esophagus | HGIN | regulation of autophagy | 84/2587 | 317/18723 | 1.39e-09 | 1.08e-07 | 84 |
GO:190180020 | Esophagus | HGIN | positive regulation of proteasomal protein catabolic process | 41/2587 | 114/18723 | 2.25e-09 | 1.67e-07 | 41 |
GO:190305219 | Esophagus | HGIN | positive regulation of proteolysis involved in cellular protein catabolic process | 45/2587 | 133/18723 | 3.55e-09 | 2.53e-07 | 45 |
GO:000697927 | Esophagus | HGIN | response to oxidative stress | 107/2587 | 446/18723 | 3.91e-09 | 2.76e-07 | 107 |
GO:003243427 | Esophagus | HGIN | regulation of proteasomal ubiquitin-dependent protein catabolic process | 45/2587 | 134/18723 | 4.64e-09 | 3.12e-07 | 45 |
GO:007233127 | Esophagus | HGIN | signal transduction by p53 class mediator | 49/2587 | 163/18723 | 5.71e-08 | 3.06e-06 | 49 |
GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
GO:003243620 | Esophagus | HGIN | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 32/2587 | 90/18723 | 1.71e-07 | 8.47e-06 | 32 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK3 | SNV | Missense_Mutation | | c.1585N>A | p.Leu529Met | p.L529M | Q9H4B4 | protein_coding | tolerated(0.51) | possibly_damaging(0.516) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PLK3 | SNV | Missense_Mutation | | c.1166C>T | p.Ala389Val | p.A389V | Q9H4B4 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.432_433insCGCCGAGCAGGGCGTGGGCACTTGACCCCC | p.Arg144_Lys145insArgArgAlaGlyArgGlyHisLeuThrPro | p.R144_K145insRRAGRGHLTP | Q9H4B4 | protein_coding | | | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PLK3 | insertion | Frame_Shift_Ins | novel | c.530_531insAATCCAGGCAGCG | p.His177GlnfsTer23 | p.H177Qfs*23 | Q9H4B4 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | novel | c.1543T>C | p.Ser515Pro | p.S515P | Q9H4B4 | protein_coding | tolerated(0.1) | possibly_damaging(0.53) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PLK3 | SNV | Missense_Mutation | | c.512N>T | p.Ser171Phe | p.S171F | Q9H4B4 | protein_coding | deleterious(0) | possibly_damaging(0.506) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | rs755159184 | c.929N>A | p.Arg310His | p.R310H | Q9H4B4 | protein_coding | tolerated(0.09) | benign(0.227) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.1910_1911insTACCTG | p.Leu637_Arg638insThrTrp | p.L637_R638insTW | Q9H4B4 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PLK3 | SNV | Missense_Mutation | novel | c.952N>C | p.Tyr318His | p.Y318H | Q9H4B4 | protein_coding | tolerated(0.05) | possibly_damaging(0.811) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | deletion | Frame_Shift_Del | | c.1006delN | p.Asn338ThrfsTer35 | p.N338Tfs*35 | Q9H4B4 | protein_coding | | | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | TAE-684 | TAE-684 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102294 | BI-2536 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | RG-1530 | RG-1530 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GW843682X | GW843682X | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | WORTMANNIN | WORTMANNIN | 17135248 |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | LINIFANIB | LINIFANIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GS 6201 | GS 6201 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | PHA-767491 | CHEMBL225519 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565601 | ONVANSERTIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GNF-PF-2301 | CHEMBL578061 | |